Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

Adjuvant CRT Linked to 83% Reduced Risk of Death in Endometrial Cancer

September 22nd 2017

Women with node-positive stage IIIC endometrial cancer assigned to adjuvant chemoradiation therapy had better survival than those assigned to chemotherapy or radiation therapy alone.

Dose-Dense Adjuvant Chemotherapy Shows Potential in Endometrial Cancer

September 22nd 2017

Dose-dense chemotherapy could be a superior option for adjuvant treatment of endometrial cancer compared with standard chemotherapy.

More Studies Needed to Improve Detection and Classification of Fallopian Tube Tumors

September 22nd 2017

Giampero (John) A. Martignetti, MD, PhD, explains that more large-size clinical trials need to be conducted to answer some of the burgeoning questions in the fallopian tube and ovarian cancer landscape.

Dr. Leitao Discusses Surgery in Gynecologic Malignancies

September 20th 2017

Mario M. Leitao, Jr, MD, FACOG, FACS, fellowship director, gynecology service, director, Minimal Access and Robotic Surgery Program, Department of Surgery, Memorial Sloan Kettering Cancer Center, discusses surgery in gynecologic malignancies.

Dr. Zamarin on Lenvatinib Plus Pembrolizumab in Endometrial Cancer

September 20th 2017

Dmitriy Zamarin, MD, PhD, a medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the combination of lenvatinib (Lenvima) plus pembrolizumab (Keytruda) in endometrial cancer.

Dr. Levine on Immunotherapy for Endometrial Cancer

September 19th 2017

Douglas A. Levine, MD, professor, Department of Obstetrics and Gynecology, director, Division of Gynecologic Oncology, NYU Langone's Perlmutter Cancer Center, discusses immunotherapy for patients with endometrial cancer.

Dr. Martignetti on Next-Generation Sequencing in Fallopian Tube Cancer

September 19th 2017

John A. Martignetti, MD, PhD, associate professor of Genetics and Genomic Sciences at the Icahn School of Medicine at Mount Sinai, network director for the Laboratory for Translational Research at the Western Connecticut Health Network, discusses next-generation sequencing for patients with fallopian tube cancer.

FDA Approves First Biosimilar for Cancer Treatment

September 14th 2017

The FDA approved the first biosimilar for the treatment of cancer. ABP-215 (bevacizumab-awwb; Mvasi), a biosimilar for bevacizumab (Avastin), is indicated for the treatment of colorectal, lung, brain, kidney, and cervical cancers in adult patients.

Pembrolizumab Plus Lenvatinib Trial in Endometrial Carcinoma Expanded

September 7th 2017

The phase Ib/II Study 111 examining the combination of pembrolizumab and lenvatinib in women with metastatic endometrial carcinoma has been expanded based on positive interim results.

Dr. Annunziata on Efforts to Prevent Gynecologic Cancers

August 15th 2017

Christina M. Annunziata, MD, PhD, investigator, Women's Malignancies Branch, head, Translational Genomics Section, National Cancer Institute, discusses the importance on efforts being done to prevent gynecologic cancers.

High Cadmium Levels Linked to Increased Endometrial Cancer Risk

August 14th 2017

Jane McElroy, PhD, discusses the association between higher cadmium levels and an increased risk of endometrial cancer.

Dr. Arend Discusses Biomarkers in Endometrial Cancer

August 11th 2017

Rebecca C. Arend, MD, assistant professor, UAB School of Medicine, UAB Department of Obstetrics and Gynecology, UAB Comprehensive Cancer Center, discusses biomarkers in endometrial cancer.

Dr. Chase on Future Treatment Landscape of Gynecologic Malignancies

August 10th 2017

Dana M. Chase, MD, FACOG, an associate professor at Creighton University, University of Arizona College of Medicine, and gynecologic oncologist with Arizona Oncology, discusses the future treatment landscape of gynecologic malignancies, including vulvar cancer, endometrial cancer, and cervical cancer.

Dr. Arend Discusses MSI Testing in Gynecologic Malignancies

August 10th 2017

Rebecca C. Arend, MD, assistant professor, UAB School of Medicine, UAB Department of Obstetrics and Gynecology, UAB Comprehensive Cancer Center, discusses microsatellite instability testing in patients with gynecologic malignancies.

Bevacizumab OS Benefit Confirmed in Cervical Cancer

August 9th 2017

Adding bevacizumab (Avastin) to chemotherapy improved overall survival for women with cervical cancer, according to final results from the phase III GOG 240 trial.

Dr. Arend Discusses Targets in Endometrial Cancer

August 2nd 2017

Rebecca C. Arend, MD, assistant professor, UAB School of Medicine, UAB Department of Obstetrics and Gynecology, UAB Comprehensive Cancer Center, discusses targeted therapies in endometrial cancer.

Adjuvant Chemotherapy Reduces Distant Recurrence Risk in Cervical Cancer

July 24th 2017

Systemic chemotherapy administered post-surgery reduced the risk for distant recurrence in women with node-positive stage IB-IIB cervical cancer.

Expert Discusses Pathology for Ovarian and Endometrial Cancer

July 20th 2017

Douglas A. Levine, MD, discusses the role of pathology in endometrial and ovarian cancer, and highlights when a patient should be tested for BRCA mutations.

Nivolumab Active in Advanced Gynecologic Cancers

July 20th 2017

Nivolumab demonstrated clinical activity in women with recurrent/metastatic cervical cancer, and was active to a lesser extent in vaginal and vulvar cancers.

ODAC Unanimously Supports Bevacizumab Biosimilar ABP-215

July 13th 2017

The FDA’s Oncologic Drugs Advisory Committee voted 17-0 to recommend approval for ABP-215, a biosimilar for bevacizumab (Avastin) to treat a range of solid tumors.